PT-141
Original price was: $55.00.$45.00Current price is: $45.00.
Product on sale
PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide melanocortin receptor agonist developed for laboratory investigation of MC1R, MC3R, MC4R, and MC5R receptor signalling pathways. Derived from melanotan II with a cyclic lactam structure and enhanced stability features, it serves as a research tool for studying central melanocortin pharmacology and neural pathway modulation. Supplied as lyophilized powder with COA verification. For laboratory research use only.
PRODUCT OVERVIEW
PT-141 (bremelanotide) was rationally developed from early melanotan research as a structurally optimized melanocortin agonist for receptor pathway investigation. The compound is a cyclic heptapeptide with molecular formula C50H68N14O10 and molecular weight approximately 1,025 g/mol (PubChem CID 9941379; CAS 189691-06-3; DrugBank DB11653; KEGG DRUG D06569; ChemSpider 8116997). The cyclic lactam bridge between Asp and Lys residues, N-terminal acetylation of norleucine (Nle), and D-phenylalanine (D-Phe) substitution at position 4 collectively produce a conformationally constrained scaffold with enhanced metabolic stability and selective receptor engagement compared to linear alpha-MSH analogues.
The compound was extensively characterized in published preclinical and clinical pharmacology studies. FDA chemistry review documentation describes bremelanotide acetate , the salt form used in the approved pharmaceutical product Vyleesi — as a synthetic cyclic heptapeptide with the equivalency statement 1.75 mg bremelanotide base = 1.89 mg bremelanotide acetate. This distinction between the free base (PubChem CID 9941379) and the acetate salt (PubChem CID 91971505; acetate hydrate CID 169434958) is important for research purity specifications and molar concentration calculations. Profound Aminos supplies the research-grade free base form for laboratory use, not the pharmaceutical salt formulation.
The mechanistic profile of PT-141 in published preclinical research centers on central MC3R and MC4R agonism in hypothalamic and limbic circuits , pathways involved in neural circuit modulation research that are mechanistically distinct from peripheral nitric oxide synthase pathways. This central neuromodulatory mechanism makes PT-141 uniquely valuable for 2026-era research into melanocortin receptor pharmacology, hypothalamic neural circuit biology, and CNS receptor agonist tool compound studies.
FOR RESEARCH USE ONLY. Not intended for consumption, parenteral administration, therapeutic, or diagnostic application of any kind. For laboratory and preclinical research exclusively.